New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK(telaprevir) in Hepatitis C
- High viral cure rate achieved with a 24-week INCIVEKcombination regimen -CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep 14, 2011 – VertexPharmaceuticals Incorporated (Nasdaq: VRTX) today announced thatthe New England Journal of Medicine (NEJM)…
September 14th, 2011
Posted in
Drug

